ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis. A combination of innovative biochip technology with cutting edge research in molecular allergology has resulted in ImmunoCAP® ISAC – the most advanced in. The immuno-solid phase allergen chip (ISAC) test (Thermo Fisher ImmunoCAP ISAC) is a microarray assay system designed to assay specific.

Author: Mot Akinozuru
Country: Togo
Language: English (Spanish)
Genre: Literature
Published (Last): 5 December 2015
Pages: 91
PDF File Size: 19.92 Mb
ePub File Size: 11.82 Mb
ISBN: 919-7-55099-583-6
Downloads: 24157
Price: Free* [*Free Regsitration Required]
Uploader: Salabar

Allergy testing Wales; Allergy testing England: Noimark and Harnik 40 did not report the number of food reintroductions that occurred following testing or clinical outcomes of any changes to dietary management. Observational study designs were eligible for inclusion only if they reported measures of additional diagnostic information provided by multiplex allergen testing; studies that assessed only concordance between multiplex allergen testing and single IgE antibody testing or other tests were not included.

The applicability of studies to current UK practice was also considered and a narrative description of potential applicability issues is provided. The comparator for this assessment was current standard care, which included allergy-focused clinical history, alternative tests of IgE antibody status single IgE antibody testingtests of clinical reactivity such as skin prick testing or allergen challenge testing or a combination of these approaches.

Fifteen studies were included in the review. In all but two cases, 5152 these studies reported no relevant outcomes. SPT, OFC, single IgE ; details of the reference standard test diagnostic accuracy studies only ; outcome measures included change to treatment or treatment plan, e.

Study design There were no restrictions on study design. Preferred temperatures for storage prior to and during shipping to ARUP. The results of the risk-of-bias assessments are summarised and presented in tables and graphs in the results of the systematic review see Study quality and are presented in full, by study, in Appendix 4.


This tool has been designed to focus on elements of study design that we considered relevant to this specific study type, and is based upon the structure of the QUADAS-2 tool.

ImmunoCAP ISAC Multiplexing – Phadia – Setting the Standard –

No studies were identified of people with difficult to manage allergic disease in the UK. The method uses solid-phase immunoassays against antigenic epitopes and measures IgE antibody concentrations in patient serum or plasma.

All presentations of allergic disease respiratory, skin, gastrointestinal, anaphylaxis were eligible for inclusion. If you live at a distance from London, or for any reason cannot attend a face-to face appointment, please start with filling in an ISAC allergy symptoms questionnaire, which will be reviewed by one of our allergy consultants.

The binding of a specific IgE to an immobilized isav component is detected by the addition of a secondary fluorescence-labeled anti-human IgE antibody.

Diagnostic accuracy of ImmunoCAP Immuno Solid-phase Allergen Chip, compared with other testing options, for the prediction of allergic response Study details Six studies 414244464749 were identified which compared the accuracy of ImmunoCAP ISAC to existing diagnostic tests SPT or single IgE tests in people with food allergies; two studies 4345 were identified of people with allergies to aeroallergens.

ISAC Test: 112 Allergy Tests in one tiny blood sample!

The inclusion criteria were expanded to allow studies that reported direct comparisons of diagnostic accuracy between single IgE testing and multiplex allergen testing, using SPTs or allergen challenge tests as the reference standard. The methods and assumptions used were largely unclear and the credibility of the assessments was questionable; therefore, these findings should be interpreted with extreme caution.

The im,unocap of studies included in this review are summarised by outcome type clinical, change to management and diagnostic accuracy and are further stratified by allergen type food and aeroallergens.


Single IgE testing and skin prick testing had comparable specificity Specimen type to collect. None of the eight studies 41 — 4749 reported the inclusion of patients with difficult to diagnose and manage allergic disease, or described inclusion criteria that could be considered immmunocap with this classification e. For questions regarding the Interface Map, please contact interface.

This indicates the importance of using confirmatory tests after the array and that the current array cannot wholly replace OFC or SPT as a diagnostic procedure.

Site built and designed by Design. Support Center Support Center. The sensitivity estimates for the two tests were equal at both cut-off points We did not identify any studies of Microtest which met the inclusion criteria for this review.

Data were extracted by one reviewer, using a piloted, standard data extraction form, and checked by a second MW and SL ; any disagreements were resolved by consensus.

The Hermansson study 33 did not report any information on clinical outcomes following changes to dietary management. The sensitivities and specificities of the individual components ISAC 50 components were not reported. Additional diagnostic information — accuracy sensitivity and specificity for the prediction of clinical reactivity, as iasc by SPTs, allergen challenge tests or response to immunotherapy, plus numbers of participants for whom multiplex allergen testing provided additional information e.

Unacceptable Conditions Ambient specimens. One study 40 was conducted in the UK, two studies 3237 were conducted in Spain, and one study was conducted in each of Finland 33 and Italy.

A conceptual model structure was developed, literature on utility scores was reviewed, and cost analyses were performed to examine the short-term costs of immunoczp possible diagnostic pathways.